Tuttle Capital Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Tuttle Capital Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$208K	–	108
2025 Q3	$208K	Hold	20,000	–	–	0.79%	49
2025 Q2	$206K	Sell	20,000 -20,000	-50%	-$205K	0.85%	44
2025 Q1	$407K	Buy	+40,000	New	+$404K	1.79%	34

Other funds holding DMAAU

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

RCM

Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tuttle Capital Management's DMAAU Position: Q4 2025 in Review

Tuttle Capital Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q4 2025, closing a stake of 20,000 shares — an estimated $208K sold.

Tuttle Capital Management first reported a position in DMAAU in Q1 2025 and held it in 3 quarters. The position peaked at $407K in Q1 2025. 5 funds tracked by Wall St. Rank hold DMAAU as of Q4 2025.

Tuttle Capital Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q4 2025 after selling out during the quarter.
Tuttle Capital Management sold 20,000 Drugs Made In America Acquisition Corp Units shares in Q4 2025, an estimated $208K.
Tuttle Capital Management first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 3 quarters.
Tuttle Capital Management's Drugs Made In America Acquisition Corp Units position peaked at $407K in Q1 2025.
5 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q4 2025.

Based on Tuttle Capital Management's 13F filing for Q4 2025, filed 8 Jan 2026.